Vir Biotechnology, Inc. Common Stock
$10.92
$0.40 (+3.80%)
$10.68Day Range$11.21
Key Statistics
Market Cap
$1.78B
Shares Outstanding
169.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 11, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$10.87
Day High
$11.21
Day Low
$10.68
Volume
1.79M
VWAP
$10.98
Prev Close
$10.52
Transactions
--
Acc. Volume
--
About Vir Biotechnology, Inc. Common Stock
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836367 employees1800 OWENS STREET, SAN FRANCISCO, CA, 94158415-906-4324IPO Oct 11, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001706431
- Composite FIGI
- BBG00H2QQ8T5
- Share Class FIGI
- BBG00H2QQ8V2
- Ticker Root
- VIR
- SIC Code
- 2836
About Vir Biotechnology, Inc. Common Stock (VIR) Stock
Vir Biotechnology, Inc. Common Stock (VIR) closed the 2026-09-17 session at $10.92, up 3.80% versus the previous close (+0.40). The stock opened at $10.87 and traded between $10.68 and $11.21 during that session. Session trading volume was 1.8M shares. The volume-weighted average price (VWAP) is $10.98.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Vir Biotechnology, Inc. Common Stock has a market capitalization of $1.78 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. VIR is listed on the XNAS exchange. The company employs approximately 367 people. Vir Biotechnology, Inc. Common Stock is headquartered in SAN FRANCISCO, CA. The recorded listing date is 2019-10-11.
On this page you can find market VIR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.